SCHEMBL4226153

SCHEMBL4226153

Cn1c(=O)c2c(c(C#N)c(Br)n2Cc2ccccc2)n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.58
KCNH2 Q12809 1/20 0.58
LMNA P02545 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
TSHR P16473 3/20 0.44
HPGD P15428 1/20 0.44
ADORA2B P29275 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HSD17B10 Q99714 2/20 0.44
ALOX15 P16050 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 2/20 0.43
USP2 O75604 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4224842 0.81 KMT2A (0.53) DPP4MAPTTSHRHPGDRXFP1
SCHEMBL8237262 0.78 DPP4 (0.68) DPP4KCNH2L3MBTL1
SCHEMBL4219958 0.77 DPP4 (0.68) DPP4KCNH2LMNASMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL4225083 0.77 DPP4 (0.67) DPP4KCNH2L3MBTL1
SCHEMBL8230984 0.74 DPP4 (0.69) DPP4KCNH2
SCHEMBL4229687 0.74 DPP4 (1.00) DPP4KCNH2
Hydrochloric Acid SCHEMBL4220187 0.74 DPP4 (0.68) DPP4KCNH2
SCHEMBL4229682 0.74 DPP4 (1.00) DPP4KCNH2
SCHEMBL23974799 0.73 HPGD (0.56) DPP4LMNASMN1; SMN2MAPTTSHR
SCHEMBL23974795 0.73 HPGD (0.56) DPP4LMNASMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
EP-1966215-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS Novartis AG (CH) 2008-09-10 EP disclosed
WO-2007071738-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 DPP4 1/4885KCNH2 1859/4885LMNA 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.